Apellis Pharmaceuticals (APLS) Other Gross PP&E Adjustments (2020 - 2025)
Apellis Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 6 years, most recently at -$62.2 million for Q4 2025.
- Quarterly results put Other Gross PP&E Adjustments at -$62.2 million for Q4 2025, down 13.9% from a year ago — trailing twelve months through Dec 2025 was -$62.2 million (down 13.9% YoY), and the annual figure for FY2025 was -$62.2 million, down 13.9%.
- Other Gross PP&E Adjustments for Q4 2025 was -$62.2 million at Apellis Pharmaceuticals, down from -$19.7 million in the prior quarter.
- Over the last five years, Other Gross PP&E Adjustments for APLS hit a ceiling of -$14.6 million in Q2 2025 and a floor of -$62.2 million in Q4 2025.
- Median Other Gross PP&E Adjustments over the past 5 years was -$19.8 million (2022), compared with a mean of -$26.5 million.
- Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 69.3% in 2021 and later rose 20.68% in 2023.
- Apellis Pharmaceuticals' Other Gross PP&E Adjustments stood at -$42.3 million in 2021, then fell by 14.45% to -$48.4 million in 2022, then decreased by 0.08% to -$48.5 million in 2023, then dropped by 12.63% to -$54.6 million in 2024, then dropped by 13.9% to -$62.2 million in 2025.
- The last three reported values for Other Gross PP&E Adjustments were -$62.2 million (Q4 2025), -$19.7 million (Q3 2025), and -$14.6 million (Q2 2025) per Business Quant data.